Stem Cell Technology Offers Promise of Huge Savings for Drug Developers
Posted on: Wednesday, 19 March 2008, 15:01 CDT
NEW YORK, March 19 /PRNewswire/ -- More than 90% of drugs entering clinical development fail to get to market, due to the lack of effectiveness or adverse side effects not detected in animal tests. These false positives could be avoided with pre-clinical tests using stem cell technologies, potentially saving drug developers millions, according to Kalorama Information's new report Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
The discovery and commercialization of a new drug costs in excess of $1 billion and requires more than 14 years. Early toxicity testing is a particular problem, since there are currently no good models for determining whether a drug will be toxic in humans. Some unsafe products advance through testing and approval, only to be pulled from the market later at a huge expense, as was the case with Vioxx and Bextra.
Though stem cell-based drug development technologies are in an early stage of development, and will most likely not become available before 2012 at the earliest, their prospects are promising.
"The excitement around stem cells has understandably been in the potential for therapy, but drug development is where they may have the most impact on healthcare," notes Bruce Carlson, publisher of Kalorama Information. "Stem cell technology could provide a virtually endless supply of liver or heart cells for testing, saving developers tens, if not hundreds of millions of dollars in direct testing fees, as well as indirect costs related to drug recalls."
Recognizing stem cells' potential, GlaxoSmithKline, AstraZeneca and Roche established a new venture in 2007, Stem Cells for Safer Medicines Ltd., to develop effective ways of using human ES cells to screen for potentially dangerous side effects of new drugs before they go into clinical trials.
Kalorama Information's report Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development discusses critical issues and trends in this exciting new field. The information and forecasts presented through 2020 were gathered through secondary research and interviews conducted with industry executives. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Stem-Cells-Worldwide-1597988/.
About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramainformation.com/.
Kalorama Information
CONTACT: Andrea Hiller of Kalorama Information, +1-212-807-2673,press@kaloramainformation.com
Web site: http://www.kaloramainformation.com/
Source: PRNewswire
Related Articles
- Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says
- Global Stem Cell Forum in China Showcases Cutting Edge Research, Focuses on New Findings for iPS Cells
- VistaGen CEO to Present Overview of Recent Stem Cell-Based Drug Discovery and Development Advances at Society of Biomolecular Sciences Symposium
- Stem Cell Therapy International Acquires Exclusive Worldwide Rights to New, Anti-Rejection Stem Cell Technology
- Exelixis Appoints Industry Veterans to Key Clinical Research and Drug Safety Positions
- ReceptoPharm Expands Antiviral Clinical Research to South America
- Gene Logic and Roche Enter Collaboration to Discover New Development Paths for Multiple Clinical Drug Candidates
- Research and Markets: Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development
- Avera Pharmaceuticals Names Joao Siffert, M.D. As Vice President, Clinical Research and Development
- Research and Markets: Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
 |
 |
User Comments (0)
RSS Feeds